The End of Daily Insulin Shots Is Finally Here

The global basal insulin market hit $7.4 billion in 2025, with type 2 diabetes accounting for roughly 76.5% of that volume. That's a massive patient population, and a huge chunk of it struggles with the daily injection grind. Cutting the burden from 365 doses to 52 isn't just convenient; it's the kind of change that could keep more patients on therapy longer.

Think of it like exercise: the best workout plan in the world is useless if nobody sticks with it. The same logic applies to insulin.

A Duopoly Takes Shape

Lilly isn't alone in this race. Novo Nordisk's Awiqli (insulin icodec) beat Onswik to the FDA finish line, earning its U.S. approval back in March 2026. That makes the once-weekly insulin market a two-horse contest.

The road to get here wasn't smooth for either company. Novo's icodec picked up approvals in Canada, the EU, Japan, and Australia throughout 2024, but the FDA pumped the brakes. The agency issued a complete response letter (essentially a "not yet") in 2024, demanding more manufacturing information and additional data on type 1 diabetes use. Novo didn't secure U.S. approval until March 2026.

Lilly followed six months later with Onswik, which is approved only for type 2 diabetes. (The label explicitly warns against use in type 1 diabetes due to severe hypoglycemia risk.)

Now the real battle begins. Both drugs offer the same core value proposition: one weekly injection instead of seven. So the fight will come down to efficacy nuances, hypoglycemia profiles, how easy each one is to dose, and (perhaps most importantly) price.

The Pricing Wild Card

Here's where things get interesting. Lilly hasn't announced Onswik's price yet. The KwikPen will come in 500 units/mL and 1,000 units/mL strengths, with U.S. availability expected in the coming months. But the sticker price remains a mystery.

For context, Novo's Awiqli has been listed at around $121 per single-unit package, with patient programs that can bring out-of-pocket costs down to $35 to $55 per month. That sets a pricing benchmark Lilly will have to respond to, whether by matching it, undercutting it, or justifying a premium.

Investors seemed cautiously optimistic on approval day. Lilly's stock saw a brief 3% pop, closing up about 2.68% on the session. The reaction suggests Wall Street had largely priced in the approval and is now waiting on the details that actually matter: launch pricing, payer coverage, and early prescription trends.

What This Means for Patients (and the Market)

The bigger picture here isn't really about Lilly versus Novo. It's about what happens when a $7.4 billion market gets disrupted by a genuinely better patient experience.

Daily basal insulin has been the standard of care for decades. It works, but it demands a level of daily discipline that many patients can't sustain. Once-weekly options don't change the biology of insulin therapy; they change the psychology of it. Fewer decisions, fewer opportunities to skip, fewer reminders that you have a chronic disease.

With two approved weekly insulins now on the market, competition should push both companies to make access easier. Payer negotiations will intensify. Patient assistance programs will expand. And if real-world adherence data eventually shows that weekly dosing keeps patients on therapy longer (which is the whole bet), it could shift prescribing habits across the entire diabetes landscape.

For the roughly 37 million Americans living with diabetes, most of whom have type 2, this is the kind of progress that actually shows up in daily life. Not a new mechanism of action. Not a marginal improvement on a lab value. Just a simple, practical upgrade: one shot a week instead of one shot a day.

Sometimes the best innovation isn't the most complicated one. It's the one people will actually use.